CAMBRIDGE, Mass., Feb. 20 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the initiation of a multi-center, Phase II trial ...

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported the presentation of results from a 482 patient, multi-center ...

drugmaker focused on cancer and inflammation, said that it ended a Phase III trial of Velcade, a treatment for newly diagnosed multiple myeloma, early because a therapy with the drug "demonstrated ...

The typical starting dose for Velcade (bortezomib) is 1.3 milligrams (mg) per square meter of body area. The exact dosage may depend on the condition being treated. Velcade (bortezomib ...

The FDA's warning letter says that marketing for cancer drug Velcade was "not appropriate" and "false or misleading" because it used the phrases "Achieve a Complete Response" and "Your Complete ...

The FDA has approved Velcade (bortezomib injection, from Millennium) for patients with previously untreated multiple myeloma. This approval is based on results from the VISTA trial which showed a ...

New draft guidance from NICE recommended Velcade (bortezomib) as a first line treatment for some patients with multiple myeloma. The new recommendation is a welcome change of heart from NICE ...

May 19, 2003 — Editor's Note: On May 12, the U.S. Food and Drug Administration (FDA) approved Velcade (bortezomib), the first drug in its class of proteasome inhibitors, for the treatment of ...

Millennium Pharmaceuticals announced that the FDA has approved an expanded label for Velcade (bortezomib) that includes long-term overall survival (OS) data from the VISTA trial as well as dosing ...

Bortezomib (Velcade) for Relapsed/Refractory Multiple Myeloma in Canada On Jan. 31, Health Canada approved bortezomib for injection (Velcade, made by Ortho-Biotech, a division of Janssen-Ortho ...